bacteria
virus
pose
seriou
challeng
human
evolv
continu
despit
ongo
effort
antivir
drug
treat
mani
troubl
virus
approv
yet
recent
launch
new
antimicrobi
gener
hope
pathogen
around
world
becom
resist
avail
drug
extra
effort
still
need
one
current
strategi
antivir
antibiot
drug
develop
search
host
cellular
pathway
use
mani
differ
pathogen
exampl
mani
virus
bacteria
alter
lipid
synthesi
transport
build
organel
insid
infect
cell
character
interact
fundament
identifi
new
target
antivir
antibiot
drug
develop
review
discuss
virus
bacteria
subvert
cell
machineri
lipid
synthesi
transport
summaris
promis
compound
interfer
pathway
emerg
virus
multidrugresist
bacteria
constitut
seriou
public
health
problem
like
becom
global
safeti
challeng
next
decad
face
situat
need
search
new
broadspectrum
antivir
antibiot
emerg
antibiot
latestag
clinic
develop
belong
exist
antibiot
class
new
compound
direct
novel
target
fernand
marten
block
cellular
pathway
use
pathogen
combin
therapi
sever
target
interest
strategi
treat
viral
bacteri
infect
avoid
antivir
antibiot
resist
classic
studi
pathogenhost
interact
focus
protein
nucleic
acid
pathogen
host
howev
recent
year
lipidom
gain
import
virolog
bacteriolog
lipid
much
structur
compon
membran
molecul
energi
storag
also
play
import
role
cellular
signal
regulatori
process
healthi
infect
cell
lipid
composit
membran
affect
morpholog
biophys
properti
charg
curvatur
width
pack
defect
fluiditi
studi
chang
lipid
biosynthesi
pathway
transport
infect
cell
promis
research
field
mani
virus
bacteria
manipul
host
membran
lipid
flow
altanbonnet
toledo
benach
van
der
schaar
dorobantu
albulescu
strate
van
kuppeveld
review
summaris
main
pathway
lipid
synthesi
transport
hijack
virus
bacteria
drug
interfer
gener
process
virus
oblig
intracellular
pathogen
requir
host
cell
machineri
replic
dna
rna
virus
usurp
take
advantag
cellular
membran
differ
step
replic
cycl
virus
abl
induc
synthesi
new
membran
reorganis
membran
cell
compart
gener
new
organel
known
replic
organel
viral
factori
support
viral
genom
replic
assembl
viru
progeni
use
membran
organel
secretori
pathway
quit
widespread
among
rna
virus
instanc
flavivirus
dengu
viru
denv
west
nile
viru
wnv
hepat
c
viru
hcv
gillespi
hoenen
morgan
mackenzi
romerobrey
et
al
welsch
et
al
reovirus
tenorio
et
al
sever
acut
respiratori
syndrom
coronaviru
knoop
et
al
two
author
equal
contributor
exploit
endoplasm
reticulum
er
membran
golgi
apparatu
use
bunyavirus
fontana
lopezmontero
elliott
fernandez
risco
enterovirus
limpen
et
al
flock
hous
viru
fhv
build
factori
mitochondria
kopek
perkin
miller
ellisman
ahlquist
tomato
bushi
stunt
viru
tbsv
use
peroxisom
fernandez
de
castro
fernandez
baraja
nagi
risco
rubella
viru
use
lysosom
fontana
et
al
sindbi
viru
assembl
replic
complex
plasma
membran
endosom
lysosom
frolova
gorchakov
pereboeva
atasheva
frolov
develop
metabolom
lipidom
base
liquid
chromatographi
mass
spectrometri
techniqu
contribut
character
monitor
chang
amount
differ
membran
signal
lipid
viral
infect
instanc
hcv
infect
discov
increas
cellular
level
cholesterol
sphingolipid
sl
modifi
phospholipid
metabol
lead
accumul
phosphatidylcholin
pc
triglycerid
longer
polyunsatur
fatti
acid
fa
chain
diamond
et
al
gullberg
et
al
hofmann
et
al
roe
kensicki
mohney
hall
lipidom
analysi
cell
infect
relat
flavivirus
denv
wnv
reveal
mark
increas
fa
glycerophospholipid
gpl
sl
content
chotiwan
et
al
perera
et
al
allow
identifi
specif
marker
infect
exampl
lysophosphatidylcholin
liebscher
et
al
techniqu
also
allow
character
lipidom
envelop
virus
way
human
immunodefici
lipid
envelop
observ
differ
produc
cell
plasma
membran
suggest
virus
bud
specialis
membran
subdomain
enrich
particular
lipid
loriz
et
al
taken
togeth
data
prove
complex
remodel
host
lipid
metabol
induc
viral
infect
gpl
major
compon
biolog
membran
structur
base
polar
group
head
defin
charg
shape
properti
allow
interact
water
molecul
near
extern
leaflet
membran
pair
fa
hydrophob
tail
ratelimit
step
gpl
biosynthesi
reli
fa
avail
order
gener
larger
pool
fa
hcv
directli
induc
overexpress
fa
synthas
fasn
key
multienzym
complex
fa
synthesi
therefor
gpl
possibl
mechan
hcv
infect
alter
cellular
lipid
profil
liver
caus
diseas
steatosi
yang
et
al
denv
nonstructur
protein
respons
fasn
recruit
replic
factori
heaton
et
al
infect
cellular
membran
show
fasndepend
enrich
unsatur
phospholipid
lipid
signal
molecul
sphingomyelin
sm
perera
et
al
two
relat
flavivirus
wnv
usutu
viru
usuv
martinaceb
blazquez
jimenez
de
oya
escribanoromero
saiz
nonrel
alphanodaviru
fhv
kampmuel
miller
also
show
rna
replic
depend
fa
synthesi
thu
modul
fa
synthesi
effect
antivir
strategi
denv
wnv
usuv
fhv
virus
sensit
inhibitori
effect
cerulenin
two
specif
inhibitor
fasn
cerulenin
natur
product
fungu
cephalosporium
caerulen
inactiv
synthas
activ
fasn
synthet
inhibitor
also
inactiv
enoyl
reductas
thioesteras
partial
activ
fasn
rate
inactiv
synthas
rendina
cheng
design
less
reactiv
safer
classic
inhibitor
cerulenin
appropri
membran
pack
fluiditi
essenti
viral
rna
replic
membran
properti
mostli
depend
satur
grade
length
fa
hydrophob
tale
stearoylcoa
desaturas
ratelimit
enzym
biosynthesi
monounsatur
fa
satur
fa
precursor
catalys
format
cisdoubl
bond
posit
stearoyl
palmitoylcoa
brome
mosaic
viru
bmv
requir
unsatur
fa
mutat
host
fa
desaturas
inhibit
bmv
replic
lee
ishikawa
ahlquist
synthet
piperidinearyl
ureabas
inhibitor
develop
specif
block
proven
impair
hcv
denv
infect
cell
cultur
gullberg
et
al
nguyen
et
al
inhibitor
claim
promis
candid
treat
variou
diseas
includ
cancer
alzheim
diseas
viral
infect
recent
novel
inhibitor
develop
report
review
uto
pc
phosphatidylethanolamin
pe
abund
gpl
cell
synthes
two
differ
metabol
rout
cholin
ethanolamin
polar
head
diacylglycerol
backbon
socal
kennedi
pathway
exploit
way
mammalian
cell
cdpdag
pathway
main
pc
sourc
yeast
altern
pathway
consist
lineal
rout
pe
suffer
three
figur
schemat
summari
host
lipid
synthesi
transport
pathway
use
virus
bacteria
compound
interfer
pathway
antivir
antibiot
activ
indic
disrupt
lipid
raft
affect
west
nile
viru
newcastl
diseas
viru
human
immunodefici
influenza
bovin
parainfluenza
syncyti
virus
salmonella
typhimurium
shigella
mycobacterium
avium
pseudomona
aeruginosa
chlamydia
trachomati
infect
inhibit
phospholipas
impair
hepat
c
viru
hcv
replic
inhibit
hmgcoa
reductas
statin
interfer
infect
mani
virus
bacteria
west
nile
viru
wnv
dengu
viru
denv
tomato
bushi
stunt
viru
chlamydia
pneumonia
staphylococcu
aureu
staphylococcu
pneumonia
mycobacterium
tuberculosi
klebsiella
pneumonia
escherichia
coli
coxiella
burnetii
global
pc
synthesi
significantli
enhanc
infect
mani
ssrna
virus
denv
fhv
polioviru
hcv
castorena
stapleford
miller
vanc
trip
paddon
zhang
et
al
moreov
bmv
replic
protein
interact
recruit
site
viral
replic
delet
yeast
mutant
bmv
replic
inhibit
zhang
et
al
hand
plant
tombusvirus
tbsv
cucumb
necrosi
viru
carnat
italian
ringspot
viru
unrel
insect
nodamura
viru
requir
high
level
pe
viral
replic
site
virus
take
advantag
increas
pe
level
yeast
cell
wherea
deplet
pe
level
reduc
viral
replic
xu
nagi
pe
small
head
result
conic
shape
propos
contribut
induct
characterist
neg
curvatur
singlemembran
vesicl
spherul
vrc
altanbonnet
addit
replic
complex
tbsv
rnadepend
rna
polymeras
rdrp
stimul
upon
pe
bind
xu
nagi
inhibit
phosphatidylglycerol
although
investig
need
identifi
particular
pc
pe
synthesi
pathway
use
differ
virus
fact
ps
accumul
usual
associ
ps
receptordepend
uptak
apoptot
mimicri
discuss
figur
schemat
summari
phosphatidylinositol
pi
deriv
signal
pathway
trigger
bacteria
virus
compound
interfer
pathway
antivir
antibiot
activ
indic
listeria
use
inib
effector
engag
host
receptor
met
stimul
recruit
bacteri
entri
site
activ
produc
pi
result
reorganis
cytoskeleton
favour
entri
listeria
listeria
chlamydia
addit
recruit
plasma
membran
produc
pi
p
also
promot
uptak
brucella
salmonella
requir
recruit
activ
enter
cell
altern
anaplasma
phagocytophilum
shigella
need
subsequ
pathway
delay
apoptosi
moreov
shigella
entri
site
requir
enrich
pi
p
stimul
ipgd
entri
chlamydia
recruit
inclus
gener
pi
p
lead
recruit
lipid
transfer
protein
oxysterolbind
protein
osbp
mycobacterium
produc
mannosecap
lipoarabinomannan
manlam
interfer
activ
disrupt
reduc
amount
pi
p
inclus
surfac
avoid
phagosom
matur
recruit
togeth
hijack
secretori
pathway
enrich
legionella
inclus
pi
p
salmonella
effector
sopb
recruit
inclus
surfac
maintain
high
level
pi
p
ssel
effector
bind
osbp
recruit
inclus
peripheri
mani
differ
virus
recruit
exploit
host
kinas
build
viral
factori
within
reorganis
cell
membran
hepat
c
viru
encephalomyocard
viru
remodel
endoplasm
reticulum
membran
build
replic
organel
assist
gener
pi
p
replic
site
similar
manner
use
virus
picornavirus
enterovirus
coxsackieviru
human
rhinovirus
regul
lipid
raft
cholesterol
synthesi
cholesterol
sl
content
biolog
membran
defin
import
physic
biolog
properti
lipid
homogen
distribut
membran
togeth
constitut
detergentresist
domain
lipid
raft
involv
membran
traffick
cell
signal
cholesterol
critic
membran
compon
determin
membran
fluiditi
help
stabilis
curvatur
pack
defect
membran
regul
format
function
membranebound
complex
lipid
protein
virus
take
advantag
properti
make
specialis
membran
platform
rna
replic
viru
assembl
lipid
raft
proven
particip
key
step
life
virus
entri
rna
translat
viru
progeni
assembl
egress
shahsavandi
ebrahimi
hasaninejad
farahani
fact
mani
virus
sensit
inhibitor
hmgcr
ratelimit
enzym
cholesterol
biosynthesi
case
statin
use
treat
hypercholesterolaemia
human
statin
act
competit
inhibit
hmgcr
molecular
structur
similar
hmgcoa
statin
fit
catalyt
activ
site
enzym
compet
nativ
substrat
competit
reduc
rate
hmgcr
produc
mevalon
next
molecul
cascad
eventu
gener
cholesterol
stancu
sima
thu
statin
deplet
cholesterol
disrupt
lipid
raft
exampl
wnv
denv
tbsv
inhibit
lovastatin
mackenzi
et
al
rothwel
et
al
sharma
sasvari
nagi
sotoacosta
bautistacarbaj
cervantessalazar
angelambrocio
del
angel
denv
human
immunodefici
inhibit
simvastatin
bryanmarrugo
et
al
delucia
rinaldo
rappocciolo
hcv
also
sensit
differ
statin
amemiya
et
al
kim
et
al
rao
pandya
lipidom
studi
shown
increas
content
ceramid
cer
sm
flavivirusinfect
cell
cer
specif
associ
wnv
replic
viral
particl
biogenesi
sm
enrich
vrc
membran
virus
phylogenet
relat
wnv
denv
hcv
martinaceb
et
al
infect
host
factor
involv
recruit
hcv
ld
lipidmodifi
phospholipas
menzel
picornavirus
also
shown
utilis
differ
phospholipas
case
enzym
assist
genom
deliveri
virion
cytoplasm
entri
cell
stare
et
al
pirel
lipid
recent
emerg
signal
molecul
involv
nearli
aspect
cellular
regul
product
describ
play
key
regulatori
role
wide
rang
cellular
activ
includ
membran
traffick
biogenesi
via
recruit
effector
protein
relat
lipid
biosynthesi
transport
major
pool
synthes
golgi
membran
pi
type
distinguish
two
differ
isoform
contrast
inhibit
isoform
compound
effici
enterovirus
includ
polioviru
coxsackieviru
human
rhinovirus
arita
arita
et
al
roulin
et
al
hcv
hsu
et
al
lack
specif
isoform
fact
inhibit
high
concentr
rais
concern
use
antivir
agent
bish
sy
siddiqui
although
vitro
studi
found
signific
problem
cellular
viabil
vivo
studi
shown
anim
treat
relat
small
inhibitor
suffer
advers
effect
howev
given
instanc
protein
deliv
final
destin
particular
membran
vesicular
shuttl
origin
er
follow
secretori
pathway
howev
mani
lipid
nonvesicular
mode
transport
faster
vesicular
traffick
produc
local
lipid
enrich
consider
asymmetri
lipid
composit
membran
nonvesicular
transport
also
ensur
suppli
lipid
organel
secretori
pathway
mitochondria
lipid
insolubl
water
nonvesicular
transport
shield
waterrich
cytoplasm
protein
hold
intern
hydrophob
pocket
lipid
transfer
protein
ltp
often
act
region
one
organel
nm
away
anoth
membran
socal
mcss
wong
copic
levin
plant
induc
ltp
express
secret
defenc
mechan
pathogen
kushwaha
singh
basu
chakraborti
ooi
et
al
park
et
al
sohal
palla
jenkin
hand
anim
virus
hijack
ltp
mobilis
cholesterol
sl
build
replic
neoorganel
best
document
case
describ
next
section
cer
transfer
protein
cert
fourphosph
adaptor
protein
mediat
traffic
sl
precursor
ltp
accumul
sl
replic
site
good
target
interfer
flavivirus
cert
respons
transfer
cer
er
golgi
synthesi
complex
sl
take
place
hanada
et
al
cert
necessari
hcv
egress
bish
et
al
pharmacolog
inhibit
synthet
compound
dramat
impair
hcv
releas
aizaki
et
al
yasuda
et
al
moreov
cert
osbp
regul
protein
kinas
phosphoryl
form
ltp
inact
amako
sy
siddiqui
drug
interf
host
protein
kinas
pkdspecif
smallmolecul
inhibitor
harikumar
et
al
might
becom
effici
antivir
dock
golgi
shuttl
glucosylceramid
godi
et
al
substrat
subset
complex
glycosphingolipid
local
hcv
replic
site
mediat
accumul
lactosylceramid
vrc
deplet
disrupt
hcv
replic
complex
impair
hcv
replic
khan
et
al
niemannpick
type
protein
discov
studi
human
neurodegen
diseas
character
disrupt
subcellular
cholesterol
transport
glycoprotein
transmembran
domain
local
late
endosom
transient
lysosom
transgolgi
network
act
tandem
carri
transfer
extracellular
recycl
free
cholesterol
endosomallysosom
system
transgolgi
network
er
ioannou
cell
receptor
ebola
viru
marburg
viru
filovirus
carett
et
al
develop
specif
inhibitor
lu
et
al
administr
multipl
cation
amphiphil
induc
accumul
cholesterol
endosom
lysosom
inhibit
ebola
entri
infect
shoemak
et
al
target
also
impair
replic
rna
virus
denv
poh
et
al
hepat
e
viru
yin
ambardekar
lu
feng
found
cellular
receptor
virus
advers
effect
viral
replic
treatment
deplet
must
due
effect
postentri
step
case
hcv
take
advantag
cellular
endosom
exosom
pathway
egress
host
cell
block
releas
viral
particl
inhibit
therefor
transport
function
multivesicular
bodi
lead
accumul
matur
viral
particl
exosom
moreov
lead
format
larg
dysfunct
lysosomelik
structur
mediat
degrad
viral
particl
elgner
et
al
bacteria
develop
number
strategi
modifi
host
lipid
infect
natur
effect
chang
fulli
understood
known
bacteria
manipul
lipid
surviv
insid
eukaryot
cell
spread
trigger
cell
death
toledo
benach
signal
cascad
relat
cholesterol
sl
phosphoinositid
particularli
relev
bacteri
infect
mani
differ
bacteria
need
cholesterol
enter
cell
build
neoorganel
stehr
elamin
singh
howev
bacteria
synthet
cholesterol
need
obtain
infect
cell
acid
sphingomyelinas
asm
one
hydrolas
gener
cer
sm
asm
activ
produc
cerenrich
domain
plasma
membran
use
bacteria
enter
cell
trigger
apoptosi
hand
asm
also
crucial
involv
host
respons
pathogen
bacteria
final
phosphoinositid
ptdin
relat
enzym
control
mani
process
includ
vesicular
traffick
actin
polymeris
differ
signal
cascad
modifi
membran
phagocytosi
activ
endocyt
pathway
bacteria
hijack
pathway
togeth
ltp
summaris
strategi
use
differ
pathogen
bacteria
subvert
lipid
synthesi
transport
target
pathway
gener
new
effici
antibiot
summaris
figur
de
novo
cholesterol
biosynthesi
occur
er
convers
hmgcoa
mevalon
hmgcr
cellular
cholesterol
level
also
increas
uptak
cholesterol
bound
lowdens
lipoprotein
ldl
via
ldl
receptor
cellular
cholesterol
level
high
transport
cell
broken
bile
acid
steroid
esterifi
store
ld
eukaryot
cell
cholesterol
sl
main
compon
membran
microdomain
known
lipid
raft
microdomain
contain
tightli
pack
receptor
cluster
signal
protein
involv
mani
signal
transduct
pathway
anaplasma
phagocytophilum
brucella
speci
enter
cell
lipid
raftdepend
manner
naroeni
port
xiong
lin
rikihisa
pharmacolog
disrupt
cholesterol
flow
impair
assembl
lipid
raft
thu
treatment
xiong
rikihisa
ketoconazol
filipin
iii
watarai
makino
fujii
okamoto
shirahata
make
bacteria
incap
infect
cell
chlamydia
develop
differ
strategi
incorpor
lipid
via
vesicular
nonvesicular
transport
hackstadt
scidmor
rockey
hatch
mcclarti
wyli
hatch
mcclarti
cholesterol
deplet
jutra
abrami
dautryvarsat
korhonen
et
al
simvastatin
erkkila
et
al
beatti
acylcoa
cholesterol
acyltransferas
inhibitor
peter
byrn
shown
elementari
bodi
extracellular
infecti
stage
chlamydia
attach
cholesterolrich
site
plasma
membran
howev
import
lipid
raft
chlamydia
entri
matter
controversi
studi
shown
chlamydia
enter
cell
way
depend
lipid
raft
gabel
elwel
van
ijzendoorn
engel
norkin
wolfrom
stuart
contradictori
result
attribut
studi
variou
bacteri
isol
differ
host
cell
enter
cell
phagocytophilum
brucella
mycobacterium
salmonella
chlamydia
coxiella
burnetii
establish
replic
inclus
membranebound
compart
deriv
phagosom
organel
endocyt
pathway
alpuchearanda
berthiaum
mock
swanson
miller
heinzen
scidmor
rockey
hackstadt
niu
yamaguchi
rikihisa
oh
et
al
although
bacteria
lack
gene
cholesterol
biosynthesi
cholesterol
content
increas
infect
cell
particular
chlamydia
spp
c
burnetii
phagocytophilum
modul
host
cholesterol
homeostasi
level
gene
transcript
ldl
receptor
hmgcr
gilk
lin
rikihisa
chlamydia
downregul
cholesterol
efflux
requir
de
novo
cholesterol
synthesi
bashmakov
zigangirova
pashko
kapotina
petyaev
wherea
phagocytophilum
alter
ldl
uptak
infect
cell
caus
twofold
increas
cholesterol
content
xiong
et
al
c
burnetii
increas
cholesterol
content
infect
cell
czyz
et
al
howe
heinzen
earli
stage
infect
inclus
membran
c
burnetii
low
level
cholesterol
later
stage
amount
cholesterol
increas
suggest
tempor
regul
cholesterol
biosynthesi
uptak
c
burnetii
shown
sensit
treatment
statin
howe
heinzen
mycobacterium
salmonella
need
lipid
raft
entri
intracellular
cholesterol
import
infect
mention
mycobacterium
synthes
cholesterol
need
obtain
cholesterol
host
altern
mean
gene
cluster
abclikeatpdepend
system
import
cholesterol
bacteria
disrupt
cholesterol
metabol
diminish
mycobacterium
entri
kaul
anand
verma
replic
de
chastelli
thilo
miner
chang
pandey
sassetti
sherman
mohn
et
al
parihar
et
al
russel
cardona
kim
allain
altar
subsequ
stage
infect
nesbitt
et
al
pandey
sassetti
salmonella
use
pathogen
island
type
iii
secret
system
local
lumen
inclus
mediat
esterif
cholesterol
haraga
ohlson
miller
nawabi
catron
haldar
pharmacolog
disrupt
cholesterol
statin
catron
et
al
huang
reduc
intracellular
salmonella
growth
bacteria
pseudomona
aeruginosa
kowalski
pier
staphylococcu
pneumonia
bergman
et
al
staphylococcu
aureu
jerwood
cohen
although
incorpor
cer
lipid
raft
essenti
initi
cell
defenc
pathogen
salmonella
huang
mccollist
myer
jonescarson
voelker
vazqueztorr
process
use
bacteria
infect
cell
mycobacteriumcontain
vacuol
phagosom
process
mediat
elimin
bacteria
vazquez
et
al
mycobacterium
avoid
host
defenc
via
pi
signal
thu
mycobacterium
tuberculosi
synthes
glycosyl
phosphoinositid
mannosecap
lipoarabinomannan
manlam
beatti
et
al
fratti
chua
vergn
deret
furthermor
phosphatas
activ
sapm
mptpb
mptpa
reduc
amount
ptdin
p
mycobacteriumcontain
vacuol
surfac
chua
deret
manlam
phosphatas
effector
interfer
phagosom
matur
degrad
bacteria
castandet
et
al
singh
et
al
interestingli
asm
also
import
mycobacterium
infect
pharmacolog
inhibit
asm
imipramin
godbol
et
al
infect
asmdefici
mice
utermohlen
herz
schramm
kronk
show
growth
tuberculosi
mycobacterium
smegmati
mycobacterium
avium
block
moreov
asmdefici
mice
resist
mycobacterium
lethal
infect
wildtyp
mice
addit
neisseria
pseudomona
trigger
asm
activ
cer
releas
assembl
cerenrich
raft
essenti
infect
grassm
et
al
grassm
et
al
hauck
et
al
cerenrich
platform
serv
scaffold
recruit
cellular
receptor
cystic
fibrosi
transmembran
conduct
regul
use
pseudomona
enter
cell
schroeder
et
al
defici
asm
specif
pharmacolog
inhibit
block
neisseria
grassm
et
al
hauck
et
al
simoni
hebl
gulbin
schneiderschauli
schubertunkmeir
e
coli
falcon
et
al
demonstr
potenti
broadspectrum
antibiot
chlamydia
incorpor
lipid
storag
organel
inclus
lumen
cocchiaro
kumar
fischer
hackstadt
valdivia
machineri
synthet
gpl
pe
phosphatidylglycerol
ps
need
hijack
hostderiv
lipid
fa
chlamydia
also
need
transport
cholesterol
sl
bacteri
cell
wall
yao
cherian
frank
rock
yao
dodson
frank
rock
close
associ
golgi
apparatu
sm
synthet
chlamydia
inclus
chlamydia
intercept
exocyt
transport
smcontain
vesicl
redirect
inclus
wolf
hackstadt
purpos
chlamydia
also
use
cert
whose
role
infect
discuss
two
mayor
signal
cascad
propos
listeria
invas
mengaud
et
al
shen
naujoka
park
ireton
two
pathway
depend
virul
factor
inia
inib
inib
interact
natur
receptor
met
marino
braun
cossart
ghosh
shen
et
al
trigger
activ
transloc
listeria
monocytogen
entri
site
subsequ
signal
cascad
produc
increas
lipid
product
particular
pi
ireton
et
al
ireton
payrastr
cossart
recruit
effector
actin
reorganis
cascad
cytoskelet
rearrang
critic
l
monocytogen
invas
inhibitor
wortmannin
block
infect
ireton
et
al
shigella
infect
site
internalis
coloc
pi
p
produc
particip
bacteri
phosphatas
ipgd
accumul
plasma
membran
reduc
tether
forc
favour
entri
pathway
activ
regul
antiapoptot
effector
trigger
howev
block
wortmannin
affect
shigella
entri
suggest
activ
involv
invas
later
step
infect
lafont
tran
van
nhieu
hanada
sansonetti
van
der
goot
pendari
et
al
phagocytophilum
also
take
advantag
pathway
delay
apoptosi
someth
observ
experi
pharmacolog
inhibit
khanal
sultana
catrava
carlyon
neelakanta
sarkar
et
al
brucella
also
requir
activ
enter
cell
replic
guzmanverri
et
al
salmonella
modul
pideriv
signal
differ
stage
infect
via
bacteri
phosphatas
effector
sopb
wellunderstood
sopbdepend
process
convert
pi
pi
plasma
membran
produc
doubl
effect
first
reduct
interact
membran
cytoskeleton
lead
bacteri
invas
terebiznik
et
al
second
recruit
akt
activ
cell
surviv
pathway
avoid
apoptosi
sopb
also
reduc
pi
ps
level
salmonella
vacuol
surfac
charg
diminish
avoid
fusion
lysosom
bakowski
et
al
anoth
essenti
sopb
function
salmonella
replic
recruit
inclus
surfac
requir
maintain
high
level
pi
p
bujni
et
al
hernandez
hueffer
wenk
galan
two
studi
auwet
et
al
auwet
yu
arena
guttman
finlay
show
ssel
anoth
salmonella
effector
interact
lipid
transfer
protein
osbp
enhanc
salmonella
replic
probabl
modifi
lipid
composit
replic
vacuol
contrast
mycobacterium
alter
pi
p
level
dual
strategi
mycobacterium
encod
differ
phosphatas
effector
arrest
phagosom
matur
avoid
elimin
reduc
amount
pi
p
mycobacterium
inclus
surfac
castandet
et
al
singh
et
al
mycobacterium
also
express
glycosyl
pi
analogu
manlam
inhibit
activ
kinas
involv
pi
p
product
chlamydia
activ
phosphoinositidedepend
signal
pathway
alzeer
et
al
zou
et
al
favour
infect
surviv
shown
import
chlamydia
listeria
infect
addit
activ
requir
listeria
invas
blockad
impair
entri
without
perturb
plasma
membran
content
pi
pi
pizarrocerda
et
al
although
particip
listeria
infect
well
understood
result
suggest
postentri
signal
role
legionella
modifi
pi
flow
number
effector
interfer
endocyt
secretori
pathway
commun
er
legionella
pneumophila
hijack
pc
diacylglycerol
legionellacontain
vacuol
membran
viner
chetrit
ehrlich
segal
furthermor
known
l
pneumophila
enrich
inclus
membran
pi
p
manner
brombach
et
al
weber
ragaz
reu
nyfel
hilbi
addit
treatment
inhibitor
reduc
l
pneumophila
replic
hubber
et
al
confirm
import
legionella
infect
howev
requir
l
pneumophila
entri
replic
matter
debat
charpenti
et
al
khelef
shuman
maxfield
tachado
samrakandi
cirillo
weber
et
al
chlamydia
recruit
high
level
membran
inclus
recruit
lipid
transfer
protein
osbp
way
although
role
still
unclear
osbp
probabl
particip
inclus
membran
remodel
modifi
lipid
composit
moorhead
jung
smirnov
kaufer
scidmor
someth
could
make
chlamydia
sensit
inhibitor
osbp
although
littl
known
bacteria
interfer
lipid
traffick
report
bacteria
hijack
ltp
best
document
case
describ
pharmacolog
inhibit
genet
defici
studi
show
use
phagocytophilum
brucella
recruit
produc
accumul
cholesterol
inclus
phagocytophilum
moreov
treatment
inhibitor
block
transport
cholesterol
bacteri
inclus
stop
bacteri
growth
evidenc
essenti
role
ltp
infect
xiong
et
al
xiong
rikihisa
case
brucella
lipid
raft
import
entri
bacteria
host
cell
watarai
makino
michikawa
et
al
import
mainten
cholesterolrich
lipid
raft
target
block
brucella
infect
therefor
mice
resist
brucella
infect
watarai
makino
fujii
et
al
effici
also
c
burnetii
chlamydia
trachomati
beatti
howe
heinzen
role
infect
still
unknown
mention
cert
transport
cer
er
membran
golgi
apparatu
sm
synthas
transform
sm
chlamydia
synthes
sl
essenti
biogenesi
bacteri
inclus
replic
bacteria
van
ooij
et
al
cryoelectron
microscopi
immunogold
label
show
cert
recruit
bacteri
inclus
chlamydia
use
cert
transport
cer
er
bacteri
inclus
sm
synthesi
derr
swiss
agaiss
elwel
et
al
sm
incorpor
inclus
membran
bacteri
cell
wall
compound
report
specif
cert
inhibitor
howev
certknockout
cell
sl
transport
still
work
strongli
impair
transport
carabeo
mead
hackstadt
elwel
et
al
kochedelmann
et
al
result
suggest
inhibitor
cer
transport
cert
oxysterolbind
proteinrel
protein
belong
osbprel
protein
famili
act
cholesterol
sensor
modul
format
mcss
late
endosom
er
recent
report
coxiella
recruit
mcss
form
bacteri
inclus
er
follow
chang
membran
properti
inclus
vacuol
justi
et
al
wallqvist
et
al
attach
coxiellacontain
vacuol
membran
ntermin
ankyrin
repeat
involv
proteinprotein
interact
specif
function
infect
still
unclear
therapeut
approach
base
specif
factor
hostpathogen
interact
promis
avenu
overcom
treatment
failur
infecti
diseas
lipid
gain
import
target
antivir
antibiot
develop
mani
virus
bacteria
use
lipid
build
neoorganel
replic
persist
inhibitor
synthesi
cholesterol
cer
sl
fa
phospholipid
interfer
growth
mani
pathogen
besid
drug
protein
kinas
target
signal
pathway
need
infect
figur
summaris
current
knowledg
host
lipid
synthesi
transport
signal
pathway
use
virus
bacteria
compound
interfer
pathway
may
becom
effici
antivir
antibiot
moreov
drug
test
virus
might
effici
also
bacteria
vice
versa
notabl
target
lipid
transport
may
produc
less
toxic
antivir
antibiot
intracellular
pathogen
depend
specif
ltp
make
neoorganel
although
cell
may
one
ltp
function
within
context
highthroughput
screen
clinic
test
compound
provid
rapid
mean
identifi
undiscov
antivir
antibiot
function
wellcharacter
molecul
target
lipid
metabol
flow
author
declar
conflict
interest
